Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-42.84	-51.09	-643.09	-222.8	-556.96	-360.18
Depreciation & Amortization	73.15	60.74	43.56	38.53	20.72	12.75
Stock-Based Compensation	49.52	44.87	36.91	44.25	38.14	29.57
Other Adjustments	-0.97	-3.57	73.16	-6.33	10.89	17.97
Change in Receivables	-27.84	-27.82	-6	-11.26	-1.06	0.85
Changes in Inventories	0.61	5.02	-3.77	-39.42	-1.21	0.12
Changes in Accounts Payable	-3.59	-0.09	-17.56	24.76	2.06	2.47
Changes in Accrued Expenses	17.48	28.84	-31.06	22.32	22.18	16.68
Changes in Income Taxes Payable	-	0.85	-0.04	-0.04	-0.37	17.1
Changes in Unearned Revenue	-1.47	-2.82	-6.12	-15.78	-12.93	38.3
Changes in Other Operating Activities	-20.84	-17.98	1.53	-6.06	-7.79	5.26
Operating Cash Flow	39.61	37.78	-237.48	-280.02	-186.29	-14.79
Capital Expenditures	-0.12	-	-	-	-	-5.1
Purchases of Intangible Assets	-68.55	-58.16	-36.21	-41.59	-28.37	-19.05
Purchases of Investments	-242.2	-237.14	-125.76	-443.94	-385.39	-547.08
Proceeds from Sale of Investments	319.22	323.6	326.33	334.58	381.99	433.6
Payments for Business Acquisitions	-	-	-65	-	-	-
Other Investing Activities	-0.32	-0.4	-0.04	-0.67	-0.79	-
Investing Cash Flow	8.15	27.89	99.33	55.78	-32.55	-137.62
Long-Term Debt Issued	-	-	-	-	316.25	-
Long-Term Debt Repaid	-	-68.9	-	-	-211.32	-
Net Long-Term Debt Issued (Repaid)	-	-68.9	-	-	104.93	-
Issuance of Common Stock	37.25	37.54	141.52	222.23	27.11	239.89
Net Common Stock Issued (Repurchased)	37.25	37.54	141.52	222.23	27.11	239.89
Other Financing Activities	-2.1	-2.1	-2.1	-2.1	-11.98	-2.1
Financing Cash Flow	-32.98	-33.47	139.42	218.75	117.57	231.68
Effect of Exchange Rate Changes on Cash and Cash Equivalents	1.68	2.29	-0.91	1.98	-2.79	1.71
Net Cash Flow	16.47	34.5	0.36	-3.51	-104.07	80.98
Free Cash Flow	39.49	37.78	-237.48	-280.02	-186.29	-19.89
Free Cash Flow Growth	4.53%	-	-	-	-	-
FCF Margin	7.37%	7.70%	-101.84%	-192.80%	-170.19%	-15.09%
Free Cash Flow Per Share	0.42	0.42	-3.01	-3.77	-2.92	-0.33
Levered Free Cash Flow	43.81	-19.88	-335.01	-87.08	-150.9	-92.52
Unlevered Free Cash Flow	7.12	10.48	-337.41	-364.05	-297.46	-112.23

Updated May 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q